Posted by Michael Wonder on 24 Nov 2023
Atopic dermatitis drug Adtralza passes insurance panel at ultrafast speed
10 November 2023 - LEO Pharma's Adtralza (tralokinumab), the second biologic approved to treat atopic dermatitis, and GSK's Trelegy 200 Ellipta (fluticasone/umeclidinium/vilanterol), a triple inhaler asthma medication with an increased steroid dose, have won recognition for reimbursement.
In contrast, Antengene's Xpovio (selinexor) and Meditip's Yondelis (trabectedine) tried again to enter the reimbursement system but failed to cross the Pharmaceutical Benefits Evaluation Committee threshold.
